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Abstract
While pneumococcal conjugate vaccines have been implemented in most countries worldwide, use in Asia has lagged in
part because of a lack of data on the amount of disease that is vaccine preventable in the region. We describe
pneumococcal serotypes elicited from 111 episodes of invasive pneumococcal disease (IPD) from 2005 to 2013 among
children and adults in Pakistan. Seventy-three percent (n = 81) of 111 IPD episodes were cases of meningitis (n = 76 in
children 0–15 years and n= 5 among adults). Serotypes were determined by target amplification of DNA extracted from
pneumococcal isolates (n = 52) or CSF specimens (n = 59). Serogroup 18 was the most common serogroup causing
meningitis in children ,5 years, accounting for 21% of cases (n = 13). The 10-valent pneumococcal conjugate vaccine (PCV
10) or PCV10- related serotypes were found in 61% (n = 47) of childhood (age 0–15 years) meningitis episodes. PCV-13
increased this coverage to 63% (one additional serotype 19A; n = 48). Our data indicate that use of PCVs would prevent a
large proportion of serious pneumococcal disease.
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Introduction
Streptococcus pneumoniae is a major cause of childhood mortality
worldwide. The World Health Organization estimates that
approximately 0.5 million deaths among HIV-negative children
,5 years were attributed to pneumococcal disease in 2008 [1]. Up
to 80% of these deaths occurred in children residing in the
developing world [2]. With the advent of pneumococcal conjugate
vaccines (PCV), invasive pneumococcal disease (IPD) and pneu-
mococcal pneumonia in children are now preventable illnesses.
However, reduction in rates of IPD is dependent on the
proportion of disease caused by vaccine serotypes. Although
current PCV10 and PCV13 formulations include the most
common serotypes causing IPD among children worldwide [3],
complex epidemiology and variation of strains among geograph-
ical regions suggest that gaps may exist in vaccine coverage for
prevalent pneumococcal serotypes circulating in some populations
[4]. Limited recent data from South East Asia suggests that the
proportion of IPD covered by PCV might be lower in this region
than elsewhere [5]. IPD surveillance in Bangladesh has shown that
from 2004 to 2007 only 38% of meningitis and 42% of
nonmeningitis infections were covered by PCV10 [6].
Mastro et al reported pneumococcal serotypes causing pneu-
monia in 87 IPD cases from 1986–1989 in Rawalpindi, Pakistan
[7]. Serotype 19F was found to be the most common serotype
causing pneumonia among children (n = 28, 32.2%), followed by
serotype 31 (n = 13, 14.9%), serotype 16 (n = 12, 13.8%), serotype
19A (n = 11, 12.6%), serotype 9V (n = 9, 10.4%), serotype 6A
(n = 4, 4.6%), serotype 15C (n = 4, 4.6%), serotype 5 (n = 2, 2.3%),
and each of serotypes 1, 6B, 9A, and 18A (n = 4, 4.6%). Only
47.1% of these serotypes are covered by PCV 10. Since the
publication of this data in 1991, no further studies have been
undertaken. To provide more recent data on the potential for
PCV to reduce disease in the region, we report pneumococcal
serotypes elicited by PCR in 111 IPD episodes in Pakistan from
2005–2013.
Methods
Data sources
Isolates were obtained from several sources. From 2005 to 2008,
pneumococci isolated from routine microbiological culture of
sterile body fluids from both adults and children were cryopre-
served at 270uC at the Aga Khan University Infectious Disease
Research Laboratory and serotyped. In 2009, Johns Hopkins
Bloomberg School of Public Health funded a meningitis surveil-
lance project through the GAVI Alliance’s Hib Initiative to study
the impact of introduction of Haemophilus influenzae type b (Hib)
vaccine in Pakistan. In this study, cerebrospinal fluid (CSF)
specimens were obtained from children less than 5 years of age at
sentinel surveillance sites in lower Sindh. Surveillance sites
included secondary and tertiary care hospitals in the districts of
Karachi, Matiari, and Hyderabad, with an overall population of
21.5 million [8], [9], with 60–80% of the population residing in
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urban areas. CSF samples collected in the study were subjected to
polymerase chain reaction (PCR)-based detection of common
agents of purulent meningitis. Culture was not performed because
of our previous experience of low yield, as the vast majority of CSF
specimens are obtained after initiation of antimicrobial therapy.
This study concluded in 2013. Of 288 samples obtained till
February 2013, 59 samples positive for pneumococci were
serotyped. A further 5 pneumococcal bloodstream isolates were
obtained from two ongoing neonatal sepsis surveillance studies in
Karachi (four cases from 2010, and one case from 2013) and 2
bloodstream isolates were obtained from an ongoing pneumonia
surveillance study in the Hyderabad district of lower Sindh (one
isolate each from 2012 and 2013).
All primary studies were approved by the Aga Khan University
Ethical Review Committee. CSF and blood samples were collected
after obtaining written informed consent from parents or
guardians of children.
(The collection of CSF samples and use for further typing was
approved in the primary Hib study by the Aga Khan University
Ethics Review Committee ERC Approval No. 869-Ped/ERC-07.
This is the study contributing the largest number of samples to this
dataset).
Culture of pneumococci, colony identification and DNA
extraction
Standard protocols as described elsewhere [10] were used for
culture of sterile body fluids (blood, CSF, ascitic, or pleural fluid).
Pneumococcal isolates were identified by optochin sensitivity and
bile solubility tests. Isolates archived in 15% glycerol with buffered
phosphate and 4 mm glass beads were revived on blood agar
media and re-identified before PCR serotyping, following the same
procedures.
DNA was isolated from pneumococcal isolates by boiling.
Briefly, a loop of pneumococcal colonies were suspended in 1 ml
of nuclease-free water and heated to 100uC for 10 minutes. Lysates
were stored at 220uC till further use.
Processing of CSF samples – DNA extraction, detection of
Streptococcus pneumoniae
From CSF specimens, DNA was extracted using the QIAmp
DNA mini kit (QIAGEN Inc. Valencia, Calif.) according to the
manufacturer’s instructions (Spin protocol). Samples were pre-
treated by suspending 20 ml of CSF in 100 ml TE buffer, 0.04 gm/
ml lysozyme, and 75 U/ml mutanolysin and incubating the
mixture at 37uC for 1 hour. Thereafter, the protocol described for
the QIAmp DNA mini kit by the manufacturer was followed.
Following DNA extraction from CSF samples, S. pneumoniae was
detected by a multiplex real time PCR for S. pneumoniae, H.
influenzae, and Neisseria meningitidis by targeting genes lytA, bexA,and
ctrA, respectively [11]. Briefly, a 25 ml reaction volume was used
with 10 mM each of forward and reverse primers and 5 mM of
probe for each respective gene. Triplex real-time PCR was
performed in Corbett Rotor-Gene 6000 (Corbette Life Science,
USA) with the following cycling conditions: 50uC for 2 minutes,
95uC for 10 minutes, followed by 50 cycles at 95uC for 15 s and
60uC for 1 minute. A Ct value of ,35 was considered positive. All
runs incorporated a negative water control and S.pneumoniae
ATCC 49619 template DNA as positive control. DNA extracted
from CSF specimens was also archived at 220uC.
PCR serotyping
Sequential multiplex PCR serotyping was performed on DNA
extracted either from bacterial isolates or from CSF samples as
described by Pai et al [12]. Thirty-three primer pairs were
grouped into 12 multiplex reactions for serogroups/serotypes 1, 3,
4, 5, 6A/B/C, 7B/C/40, 10A, 11A/D, 12F/A/44/46, 15A/F,
15B/C, 17F, 18A/B/C/F, 19F, 20, 22A/F, 23F, 33F/A/37, 35F/
47F (Pai et al) [12], 19A (Pimenta et al) [13], 2, 7A/F, 8, 9V/A,
10F/C/33C, 13, 23A, 23B, 24A/B/F, 35A/C/42, 39 (Carvalho
et al) [14], and 14, 9N/L (Dias et al) [15]. The primer for the
conserved pneumococcal polysaccharide capsule gene (cpsA) was
added as control with each multiplex reaction. Non-typeable
samples were also subjected to PCR serotyping for the following
additional serotypes/serogroups in monoplex reactions: 6C/6D,
16F, 21 (Carvalho et al) [14], and 31, 34, 35B, and 38/25F/25A
(Pai et al) [12].
Multiplex reactions contained primers for 2–4 serotypes/
serogroups and positive internal control cpsA. PCR was carried
out in reaction mixture volumes of 25 ml (22 ml for monoplexes),
with 25 mM primers, and 2X multiplex master mix (Qiagen).
Amplification was performed in Eppendorf Master Cycler
(Eppendorf, Hamburg, Germany) with the following cycling
conditions: 95uC for 15 minutes, then 35 cycles of 95uC for
30 s, 54uC for 90 s, and 72uC for 60s. PCR final extension was
performed at 72uC for 10 minutes. PCR products were
electrophoresed on 2% agarose gel stained with SYBR Green
(Sigma, USA) and visualized under UV light (GEL-DOC
molecular imager, Biorad Inc. USA).
Serotypes 1, 3, 4, 5, 14, 19A, 19F, and 23F (contained within
PCV 10 and PCV 13) were defined as vaccine serotypes (V).
Serotypes contained within serogroups 18A/B/C/F, 7A/F, 9V/A,
and 6A/B/C were classified as vaccine-related (VR) as these could
not be further resolved to individual serotypes by PCR serotyping.
Serotypes contained within the same serogroup as vaccine
serotypes were also classified as vaccine related. All other
serogroups and serotypes (including non-typeable) were classified
as non-vaccine serotypes (NV).
Results
Serotypes were elicited for 111 episodes of IPD from 2005 to
2013. Of these, 76 (68.4%) episodes were cases of meningitis (72
cases in children 0–59 months of age), while 17 were cases of non-
meningitis IPD (NM-IPD) in children aged 0–15 years. Overall, 84
(75.6%) cases were from children under 5 years. Eighteen (n = 18;
16.2%) strains of pneumococci isolated from IPD in adults and
cryopreserved from 2005 to 2008 were also serotyped. Table 1
describes IPD cases, sources and sample types, and serotypes
determined in all 111 episodes.
IPD serotypes in children 0–59 months
Serotyping by PCR was performed on 72 individual meningitis
cases. Of these, 13 cases were taken from 2005–2006 (with
archived pneumococcal isolates), and 59 cases were obtained from
the Hib meningitis study [9]. The most common serogroup
causing meningitis was serogroup 18 (n = 13), followed by
serogroup 14 (n = 7), serotype 19F (n = 6), and serotype 23B
(n = 6). The non-vaccine serotype 12F/A (detected as 12F/A/44/
46) was found in 6 cases. Five cases remained non-typeable by
PCR. These 5 were positive for lytA (detected in the CSF triplex)
as well as for cpsA genes. Serotype data has been temporally
disaggregated in Table 1 and Figure S1 in File S1. Figure 1 shows
the proportion of strains covered by PCVs among children 0–59
months with meningitis seen from 2009 to 2013.
Bacterial isolates were serotyped from five cases of neonatal
sepsis and seven cases of sepsis in children 1–59 months old
(Table 1). Four of five cases of neonatal sepsis were caused by
Pneumococcal Serotypes in Pakistan
PLOS ONE | www.plosone.org 2 June 2014 | Volume 9 | Issue 6 | e98796
T
a
b
le
1
.
IP
D
se
ro
ty
p
e
s
fr
o
m
P
ak
is
ta
n
b
y
ag
e
g
ro
u
p
an
d
sp
e
ci
m
e
n
so
u
rc
e
,
2
0
0
5
–
2
0
1
3
.
A
g
e
g
ro
u
p
a
n
d
sy
n
d
ro
m
e
S
o
u
rc
e
N
u
m
b
e
r
o
f
ca
se
s
S
e
ro
ty
p
e
s
(n
)
P
ro
p
o
rt
io
n
o
f
se
ro
ty
p
e
s
in
cl
u
d
e
d
in
P
C
V
-1
0
*
(%
)
P
ro
p
o
rt
io
n
o
f
se
ro
ty
p
e
s
in
cl
u
d
e
d
in
P
C
V
-1
3
(%
)
0
–
5
9
m
o
n
th
s
M
e
n
in
g
it
is
C
SF
7
2
4
7
/7
2
(6
5
.3
%
)
4
8
/7
2
(6
6
.7
%
)
1
3
(2
0
0
5
–
6
)
1
9
F
(4
),
1
8
A
/B
/C
/F
(2
),
1
1
A
/D
(2
),
9
V
/A
(1
),
1
5
B
/C
(1
),
2
2
A
/F
(1
),
1
(1
),
N
T
{(
1
)
8
/1
3
(6
1
.5
%
)
8
/1
3
(6
1
.5
%
)
5
9
(2
0
0
9
–
1
3
)
1
8
A
/B
/C
/F
(1
1
),
1
4
(7
),
1
9
F
(2
),
2
3
B
(6
),
1
2
F/
A
/4
4
/4
6
(6
),
5
(4
),
9
V
/A
(2
),
1
(1
),
1
5
B
/C
(1
),
1
0
A
(2
),
6
A
/B
/C
(2
),
4
(2
),
2
3
F(
2
),
1
9
A
(1
),
1
7
(1
),
8
(1
),
9
N
/L
(1
),
2
4
A
/B
/F
(1
),
3
3
F/
A
/3
7
(1
),
3
5
B
(1
),
N
T
{
(4
)
3
9
/5
9
(6
6
.1
%
)
4
0
/5
9
(6
7
.8
%
)
S
e
p
si
s
B
lo
o
d
1
2
5
(3
),
1
(2
),
2
3
A
(2
),
2
3
F
(1
),
3
(1
),
1
4
(1
),
1
0
F/
C
/3
3
C
(1
),
3
5
B
(1
)
9
/1
2
(7
5
%
)
1
0
/1
2
(8
3
.3
%
)
S
u
b
to
ta
l
8
4
5
6
/8
4
(6
6
.7
%
)
5
8
/8
4
(6
9
%
)
5
–
1
5
y
e
a
rs
M
e
n
in
g
it
is
C
SF
4
7
A
/F
(1
),
1
1
A
/D
(1
),
2
4
A
//
B
/F
(1
),
N
T
(1
)
0
/4
(0
%
)
0
/4
(0
%
)
S
e
p
si
s
B
lo
o
d
3
1
8
A
/B
/C
/F
(1
),
1
(1
),
1
9
F
(1
)
3
/3
(1
0
0
%
)
3
/3
(1
0
0
%
)
E
m
p
y
e
m
a
P
le
u
ra
l
fl
u
id
2
1
9
F
(2
)
2
/2
(1
0
0
%
)
2
/2
(1
0
0
%
)
S
u
b
to
ta
l
9
5
/9
(5
5
.6
%
)
5
/9
(5
5
.6
%
)
A
d
u
lt
s
(1
8
–
7
0
y
e
a
rs
)
M
e
n
in
g
it
is
C
SF
5
5
(1
),
1
3
(1
),
1
9
F
(1
),
2
2
A
/F
(1
),
N
T
(1
)
2
/5
(4
0
%
)
2
/5
(4
0
%
)
S
e
p
si
s
B
lo
o
d
8
1
(2
),
2
3
F
(2
),
1
3
(1
),
1
5
B
/C
(1
),
3
8
/
2
5
F/
2
5
A
(1
)
4
/8
(5
0
%
)
4
/8
(5
0
%
O
th
e
r*
*
Se
e
b
e
lo
w
5
1
9
F
(3
),
1
(1
),
1
4
(1
)
5
/5
(1
0
0
%
)
5
/5
(1
0
0
%
)
S
u
b
to
ta
l
1
8
1
1
/1
8
(6
1
.1
%
)
1
1
/1
8
(6
1
.1
%
)
T
O
T
A
L
1
1
1
7
2
/1
1
1
(6
4
.9
%
)
7
4
/1
1
1
(6
6
.7
%
)
*I
n
cl
u
d
e
s
V
ac
ci
n
e
-r
e
la
te
d
(V
R
)
se
ro
ty
p
e
s.
{ N
T
=
N
o
n
-t
yp
e
ab
le
.
**
A
sc
it
ic
fl
u
id
(n
=
3
),
sy
n
o
vi
al
fl
u
id
(n
=
1
),
u
n
kn
o
w
n
st
e
ri
le
b
o
d
y
fl
u
id
(n
=
1
).
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
9
8
7
9
6
.t
0
0
1
Pneumococcal Serotypes in Pakistan
PLOS ONE | www.plosone.org 3 June 2014 | Volume 9 | Issue 6 | e98796
PCV-10 vaccine serotypes while one case was due to serotype 3,
which is contained in PCV-13. Temporal distribution of sepsis
serotypes is shown in Figure S2 in File S1.
Overall, 66.7% of IPD serotypes from children less than 5 years
are those covered by PCV 10 (vaccine or vaccine-related
serotypes), including 65.3% (47 of 72) of meningitis and 75% (9
of 12) of non-meningitis cases. An additional 2 cases with one
serotype 19A in meningitis and one case with serotype 3 in
neonatal sepsis were potentially preventable with PCV-13,
increasing overall coverage from 66.7% to 69%.
IPD serotypes in children 5–15 years and adults
Nine pneumococcal isolates from children 5–15 years of age
and 18 isolates from adults (2005–2008) were available for
serotyping. Among the 27 strains, 16 (59.3%) were serotypes
included in PCV10 (Table 1).
Discussion
This is the first time pneumococcal serotypes responsible for
childhood meningitis are being reported from Pakistan, adding to
earlier data from Mastro et al, who reported serotypes from
pneumonia cases among children [7]. Although IPD is not a rare
illness, the complex epidemiology and surveillance difficulties have
made estimation of IPD incidence challenging. Zaidi et al reported
the incidence of pneumococcal meningitis as 81 per 100 000
infants less than 1 year of age and 20 cases per 100 000 children
less than 5 years of age in 2005 [16]. Considering this high
incidence and case fatality rates of up to 50% for pneumococcal
meningitis [17], understanding the pneumococcal serotypes
responsible for meningitis and the proportion likely to be
preventable by vaccine are valuable data for policymakers in
Pakistan and in similar countries in the region as PCV10 and
PCV13 are being introduced or being considered for introduction.
PCV 7 (Wyeth, now Pfizer) was introduced in Pakistan for the
private market in May 2006 (Pfizer, data on file). Vaccination
rates, however, have been low and inconsistent due to unafford-
able vaccine prices and inaccessibility of private pharmacy
services. We therefore consider the community data presented
here as reflecting the serotype distribution of a vaccine-naı¨ve
population. PCV10 was introduced in Pakistan as part of its
Expanded Program on Immunizations in March 2013 with
support from the GAVI Accelerated Vaccine Introductions
initiative. This report describes pneumococcal serotype distribu-
tion in IPD in Pakistan from before March 2013. Given data from
Bangladesh showing vaccine coverage closer to 40%, an overall
serotype coverage of 65.6% (PCV-10) for childhood IPD (61 of 93
serotypes) is reassuring in the wake of vaccine introduction and
roll-out. However, data from continued IPD surveillance after the
PCV10 roll-out will be a better indicator of vaccine efficacy in the
Pakistani pediatric population.
Figure 1. Vaccine coverage of pneumococcal serotypes in meningitis, Karachi and Hyderabad, Pakistan; 2009–2013 in children 0–
59 months. (V = Vaccine serotypes, VR = Vaccine-related serotypes, and NV= non-vaccine serotypes).
doi:10.1371/journal.pone.0098796.g001
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Serotype proportions we report differ from those reported by
Mastro et al [7] for pneumococcal pneumonia. Serotype 19F was
the most common serotype reported by Mastro, whereas only
9.7% of meningitis cases in children are caused by 19F.
Furthermore, serotypes 31 and 16 were also commonly seen in
pneumonia, but were not found in meningitis cases. However, this
comparison is confounded by temporal as well as regional
differences as well as possible circulation of outbreak strains. Data
should therefore be interpreted keeping in view these important
differences.
We found most pneumococcal meningitis to be due to
serogroup 18 (18A/B/C/F). Individual serotypes for serogroup
18 could not be determined due to the limitations of low-resolution
PCR and cost constraints restricting use of reference Quellung and
latex serotyping methods. Serotype 18C, which is a highly invasive
serotype [18], and included in all three pneumococcal conjugate
vaccines owing to its high prevalence in IPD globally [5], is the
most likely responsible serotype in this serogroup, however.
Although there are no definitive reports of cross-protection for
serotypes 18A, 18B, and 18F, these serotypes are considered
vaccine related by a number of investigators [19], [20]. The
incidence of these serotypes has been too low to determine
whether the 18C antigen in PCV provides cross protection. In
both meningitis and non-meningitis IPD, individual NV serotypes
did not cause a large proportion of disease. In other settings that
introduced the 7-valent PCV, some increase in NV serotypes was
seen a few years after vaccine introduction. In those settings, the
serotypes noted to increase were generally those that were most
common before PCV7 introduction [21], [22]. The most common
serogroup result found among NV serotypes was 12F/A/44/46
(unresolved to individual serotypes). In countries where either
PCV7 or PCV10 have been introduced, 12F was found to be a
common NV serotype causing IPD [17]. Continued surveillance
and improved PCR methods will be required to demonstrate if
12F will become a more common cause of IPD in the post-vaccine
era.
Our results from adult IPD cases demonstrate that the greater
proportion of serotypes in this population is covered by conjugate
vaccines as well as polysaccharide vaccines (PPV23). However, due
to paucity of adult samples in our dataset, this finding needs to be
verified in larger samples from adults with pneumococcal disease.
In other settings, use of PCV among young infants has reduced
transmission of vaccine type pneumococci from children to adults,
preventing disease in older populations [23]. Whether these
indirect benefits of PCV will occur in settings such as Pakistan still
needs to be measured.
Our work has several limitations. We were able to serotype
pneumococci from only a selected few samples submitted for
examination and, therefore, results may not represent all IPD. Our
data contain very few cases of pneumonia, which is the more
prevalent form of IPD. Serotype proportions therefore may not
represent the true proportion in the population for nonmeningitis
IPD. Moreover, use of alternative serotyping methods such as
Quellung typing or latex serotyping could have improved our
results; however, use of these methods was not possible due to cost
constraints and insufficient CSF specimen volumes.
This is the first comprehensive pneumococcal serotyping data
from Pakistan since the study by Mastro et al. These data provide
a baseline with which to compare IPD rates and serotypes
following the introduction and roll-out of PCV10 in Pakistan. We
therefore recommend continued surveillance of IPD followed by
pneumococcal serotyping for improved serotype-specific IPD
surveillance. The data hold promise that PCV will target a large
proportion of disease in the region.
Supporting Information
File SI Figure S1 & S2. Figure S1 shows pneumococcal
meningitis serotypes by year in children 0–59 years, 2005–2013 in
Hyderabad and Karachi, Pakistan. Different colors represent
numbers of meningitis cases seen for that year due to individual
serotypes. Figure S2 shows pneumococcal sepsis serotypes by year
in children 0–59 years, 2005–2013 in Hyderabad and Karachi,
Pakistan. Colors represent numbers of sepsis cases occurring each
year due to individual serotypes.
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